Margi McLoughlin, Ph.D.

Executive Director, WWBD / Partner
Margi_200x300.jpg
Margi McLoughlin, PHD is Executive Director, WWBD and Partner at Cheladv74 Ventures. Margi invests in companies working in areas aligned with the future directions of Cheladv74. She currently has responsibility for Cheladv74’s investments in 4D Molecular Therapeutics, Adapsyn, BioAtla, Cortexyme and System1. Through these investments, she works with the companies to help advance products and technologies of value to the pharmaceutical industry.
 
Margi began her career at Mallinckrodt Medical, holding positions in Discovery Research, followed by Technology Planning. In 1999, she moved to Yale University where she worked as Associate Director in the Office of Cooperative Research. Since joining Cheladv74 Worldwide Business Development in 2001, she has had roles of increasing responsibility and led transactions with multiple biotech companies, including Ablexis, Gliknik and Excaliard. In addition, Margi played a significant role in defining Cheladv74’s Centers for Therapeutic Innovation business model.
 
Margi received her BS in Chemistry from UC Irvine and holds a PhD in Chemistry from the University of California, Santa Barbara.